Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Retatrutide and Tirzepatide have garnered significant attention for their potential influence in regulating metabolic functions. This article explores the similarities and differences between ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

while tirzepatide produced up to 17.8% weight loss over 72 weeks. How It Works Retatrutide mimics three hormones: GLP-1, which suppresses appetite; GIP; and glucagon, which helps regulate blood sugar.

Novo Nordisk's weight loss drug Wegovy mimics only GLP-1. Retatrutide appears to cause even greater weight loss than tirzepatide, which has skyrocketed in demand in the U.S. Retatrutide helped ...